PT - JOURNAL ARTICLE AU - Robert P. Hirten AU - Matteo Danieletto AU - Lewis Tomalin AU - Katie Hyewon Choi AU - Micol Zweig AU - Eddye Golden AU - Sparshdeep Kaur AU - Drew Helmus AU - Anthony Biello AU - Renata Pyzik AU - Claudia Calcogna AU - Robert Freeman AU - Bruce E Sands AU - Dennis Charney AU - Erwin P Bottinger AU - Laurie Keefer AU - Mayte Suarez-Farinas AU - Girish N. Nadkarni AU - Zahi A. Fayad TI - Factors Associated with Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic AID - 10.1101/2020.12.21.20248593 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.21.20248593 4099 - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248593.short 4100 - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248593.full AB - Introduction The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in psychological distress in health care workers (HCWs). There is a need to characterize which HCWs are at increased risk of psychological sequela from the pandemic.Methods HCWs across seven hospitals in New York City were prospectively followed in an ongoing observational digital study using the custom Warrior Watch Study App. Participants wore an Apple Watch for the duration of the study measuring HRV throughout the follow up period. Surveys were obtained daily.Results Three hundred and sixty-one HCWs were enrolled. Multivariable analysis found New York City COVID-19 case count to be significantly associated with increased longitudinal stress (p=0.008). A non-significant decrease in stress (p=0.23) was observed following COVID-19 diagnosis, though there was a borderline significant increase following the 4-week period after a COVID-19 diagnosis via nasal PCR (p=0.05). Baseline emotional support, baseline quality of life and baseline resilience were associated with decreased longitudinal stress (p<0.001). Baseline resilience and emotional support were found to buffer against stressors, with a significant reduction in stress during the 4-week period after COVID-19 diagnosis observed only in participants in the highest tertial of emotional support and resilience (effect estimate −0.97, p=0.03; estimate −1.78, p=0.006). A significant trend between New York City COVID-19 case count and longitudinal stress was observed only in the high tertial emotional support group (estimate 1.22, p=0.005), and was borderline significant in the high and medium resilience tertials (estimate 1.29, p=0.098; estimate 1.14, p=0.09). Participants in the highest tertial of baseline emotional support and resilience had significantly reduced amplitude and acrophase of the circadian pattern of longitudinally collected heart rate variability.Conclusion Our findings demonstrate that low resilience, emotional support, and quality of life identify HCWs at risk of high perceived longitudinal stress secondary to the COVID-19 pandemic and have a distinct physiological stress profile. Assessment of HCWs for these features can identify and permit allocation of psychological support to these at-risk individuals as the COVID-19 pandemic and its psychological effects continue in this vulnerable population.Competing Interest StatementThe authors or their institutions did not receive any payments or services from a third party in the past 36 months with entities that could be perceived to influence the submitted work. RPH discloses consulting fees from HealthMode,Inc, Janssen Pharmaceuticals, Takeda Pharmaceuticals. Research support from Intralytix Inc. and a Crohns and Colitis Foundation Career Development Award (grant number 607934). MD declares no conflicts of interest. LT declares no conflicts of interest. KHC declares no conflicts of interest. MZ declares no conflicts of interest. EG declares no conflicts of interest. SK declares no conflicts of interest. DH declares no conflicts of interest. AB declares no conflicts of interest. RP declares no conflicts of interest. CC declares no conflicts of interest. RMF declares no conflicts of interest. BES declares no conflicts of interest. DC is co-inventor on patents filed by the Icahn School of Medicine at Mount Sinai (ISMMS) relating to the treatment for treatment-resistant depression, suicidal ideation and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), Dr. Charney is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, Dr. Charney, will be entitled to additional payments, beyond those already received, under the license agreement. Dr. Charney is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, Dr. Charney has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. Dr. Charney is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered Neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. Dr. Charney is a named co-inventor on a patent application in the US, and several issued patents outside the US filed by the ISMMS related to the use of ketamine for the treatment of post-traumatic stress disorder (PTSD). This intellectual property has not been licensed. E.P. Bottinger reports consultancy agreements with Deloitte and Roland Berger; ownership interest in Digital Medicine E.Bottinger GmbH, EBCW GmbH, and Ontomics, Inc.; receiving honoraria from Bayer, Bosch Health Campus, Sanofi, and Siemens; and serving as a scientific advisor or member of Bosch Health Campus and Seer Biosciences Inc LK declares research funding from Abbvie and Pfizer, consulting for Abbvie and Pfizer, equity ownership/stock options MetaMe Health, Trellus Health MSF declares research support from Novartis and Allergenis. G.N. Nadkarni reports employment with, consultancy agreements with, and ownership interest in Pensieve Health and Renalytix AI; receiving consulting fees from AstraZeneca, BioVie, GLG Consulting, and Reata; and serving as a scientific advisor or member of Pensieve Health and Renalytix AI. ZAF discloses consulting fees from Alexion, GlaxoSmithKline and Trained Therapeutix Discovery; Research funding from Daiichi Sankyo; Amgen; Bristol Myers Squibb; Siemens Healthineers. ZAF receives financial compensation as a board member and advisor to Trained Therapeutix Discovery and owns equity in Trained Therapeutix Discovery as co-founder. Funding StatementSupport for this study was provided by the Ehrenkranz Lab For Human Resilience, the BioMedical Engineering and Imaging Institute, The Hasso Plattner Institute for Digital Health at Mount Sinai, The Mount Sinai Clinical Intelligence Center and The Dr. Henry D. Janowitz Division of Gastroenterology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB at the Icahn School of Medicine at Mount Sinai HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study followed health care workers. Due to the sensitive nature of their data there are limitations on the public availability of the data.